Insight, China's Pharmaceutical Industry

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly...

Company Deals

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Fineline Cube Mar 24, 2026

Sinomune Pharmaceutical Co., Ltd., a China-based dermatological specialist, announced a licensing agreement with Almirall, S.A....

Company Deals

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Fineline Cube Mar 24, 2026

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced a licensing agreement with Nizhny Novgorod Chemical...

Company Deals

Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China

Fineline Cube Mar 24, 2026

Tenacia Biopharmaceuticals (Shanghai) Co., Ltd., a Bain Capital-incubated CNS specialist, announced a licensing agreement with...

Company Deals

Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights

Fineline Cube Mar 24, 2026

Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Arrotex Pharmaceuticals Pty Ltd., granting the...

Company Deals

Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets

Fineline Cube Mar 24, 2026

Rapport Therapeutics, Inc. (NASDAQ: RAPP) announced a licensing agreement with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd....

Company Deals

LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules

Fineline Cube Mar 24, 2026

Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio), an AI-enabled drug development biotech, announced a strategic partnership...

Company Deals

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Fineline Cube Mar 24, 2026

Chongqing Maile Bio-Pharm Co. Ltd. and Shenzhen Main Luck Pharmaceuticals Inc. announced a strategic partnership...

Company Deals

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Fineline Cube Mar 24, 2026

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...

Company

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...

Company Deals

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Fineline Cube Mar 24, 2026

Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...

Company Drug

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

Fineline Cube Mar 24, 2026

Qilu Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 innovative drug, QLS1317 tablets, has...

Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026

China’s National Healthcare Security Administration (NHSA) held a briefing outlining the DRG (Diagnosis‑Related Groups) Grouping...

Company Deals

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Fineline Cube Mar 24, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has entered into a strategic partnership...

Company Drug

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Fineline Cube Mar 24, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp...

Company Deals

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Fineline Cube Mar 24, 2026

Bio‑Thera Solutions Inc. (SHA: 688177) has expanded its strategic partnership with Intas Pharmaceuticals Ltd., granting...

Company

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

Fineline Cube Mar 24, 2026

Sanofi S.A. (NASDAQ: SNY) announced a comprehensive strategic upgrade of its China R&D center, establishing...

Company Drug

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Fineline Cube Mar 24, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of...

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Fineline Cube Mar 23, 2026

Novartis AG (NYSE: NVS) announced at the China Development Forum (CDF) 2026 Annual Meeting that...

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Fineline Cube Mar 23, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX18, a recombinant humanized anti‑PD‑1 monoclonal antibody...

Insight, China's Pharmaceutical Industry

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China

Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights

Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets

LexBio Partners with Hiteck Biopharma – AI-Enabled Drug Discovery Alliance Targets Inflammatory Disease Small Molecules

Chongqing Maile Bio-Pharm Partners with Main Luck Pharma on Hematoporphyrin Commercialization – Photodynamic Therapy Targets Superficial Cancers

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface

Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases

Qilu Pharma’s QLS1317 Wins NMPA Approval – First‑in‑Class MSI‑H Targeted Therapy Enters Solid Tumor Clinical Trials

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Biocytogen Partners with Moonlight Bio – Antibody‑Cell Therapy Collaboration Targets Difficult‑to‑Treat Cancers

Innovent’s IBI302 Hits STAR Trial Primary Endpoint – Dual VEGF/Complement Inhibitor Shows 16‑Week Dosing and 50% Macular Atrophy Reduction in nAMD

Bio‑Thera Expands Intas Partnership to India – BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India

Sanofi Upgrades Shanghai R&D Center to Legal Entity – Largest China Translational Medicine Hub Anchors Global Network

RemeGen Secures Fourth NMPA Approval for Disitamab Vedotin – HER2‑Low Breast Cancer with Liver Metastases Indication Expands ADC Franchise

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

You Missed

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting